Syntagon will implement a restructuring program designed to improve its offering to customers in the field of drug substance development. The company’s Sweden-based operations, Syntagon AB, will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Latvian site, SIA Syntagon Baltic, will ramp up capacity and know-how within the field of preclinical and clinical deliveries of drug substances. The moves wi...